CSL Management
Management criteria checks 1/4
CSL's CEO is Gordon Naylor, appointed in Feb 2026, has a tenure of less than a year. directly owns 0.008% of the company’s shares, worth A$5.45M. The average tenure of the management team and the board of directors is 2.7 years and 1.5 years respectively.
Key information
Gordon Naylor
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.008% |
| Management average tenure | 2.7yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
CSL: The Dip Is the Opportunity
CSL: The Dip Is the Opportunity Most people look at CSL's stock chart right now and see a problem. Down 35% from its highs, margins cut in half, and a company in the middle of its biggest restructuring in decades.My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear
Feb 17
Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook
Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up
Sep 25Is CSL Limited (ASX:CSL) Trading At A 43% Discount?
Aug 07Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly
Jun 14CSL is undervalued in High Tax Scenario
CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$1b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$3b |
| Mar 31 2025 | n/a | n/a | US$3b |
| Dec 31 2024 | n/a | n/a | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$3b |
| Dec 31 2023 | n/a | n/a | US$2b |
| Sep 30 2023 | n/a | n/a | US$2b |
| Jun 30 2023 | n/a | n/a | US$2b |
| Mar 31 2023 | n/a | n/a | US$2b |
| Dec 31 2022 | n/a | n/a | US$2b |
| Sep 30 2022 | n/a | n/a | US$2b |
| Jun 30 2022 | n/a | n/a | US$2b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | n/a | n/a | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | n/a | n/a | US$3b |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | n/a | n/a | US$2b |
| Sep 30 2019 | n/a | n/a | US$2b |
| Jun 30 2019 | US$4m | US$1m | US$2b |
Compensation vs Market: Insufficient data to establish whether Gordon's total compensation is reasonable compared to companies of similar size in the Australian market.
Compensation vs Earnings: Insufficient data to compare Gordon's compensation with company performance.
CEO
Gordon Naylor (62 yo)
Mr. Gordon Naylor, M.B.A., GradDip (Computing Studies), BEng (Hons), DipCompSc, C.P.A., GAICD, FTSE, MIE(Aust), serves as Chief Executive Officer and Managing Director at CSL Limited since February 2026. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Commercial Officer | 2.8yrs | US$3.59m | 0.0011% A$ 697.3k | |
| CEO, MD & Director | less than a year | US$3.56m | 0.0083% A$ 5.4m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Executive VP & COO | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP of Legal & Group General Counsel | 17.3yrs | US$2.31m | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Medical Officer | 7.5yrs | US$2.14m | no data | |
| Chief Digital Information Officer & Executive VP | 5.5yrs | no data | no data | |
| Senior Vice President of Research & Development Strategic Operations | no data | no data | no data | |
| Executive VP of Business Development & Enterprise Alliance Management | 3.1yrs | no data | no data | |
| First Chief Sustainability Officer | 2.7yrs | no data | no data |
Experienced Management: CSL's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | less than a year | US$3.56m | 0.0083% A$ 5.4m | |
| Independent Non-Executive Director | 4.7yrs | US$253.45k | 0.00088% A$ 578.9k | |
| Independent Non-Executive Director | 6.3yrs | US$238.62k | 0.00054% A$ 355.2k | |
| Independent Non-Executive Chairman | 8.2yrs | US$612.35k | 0.027% A$ 17.4m | |
| Independent Non-Executive Director | 7.5yrs | US$223.98k | 0.015% A$ 9.7m | |
| Independent Non-executive Director | 1.3yrs | US$135.56k | 0.00018% A$ 118.4k | |
| Independent Non- Executive Director | less than a year | no data | no data | |
| Independent Non-executive Director | 2.3yrs | US$199.34k | 0.00046% A$ 302.6k | |
| Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 1.6yrs | US$194.62k | no data | |
| Director | less than a year | no data | 0.00069% A$ 453.9k | |
| Director | less than a year | no data | no data |
Experienced Board: CSL's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/18 23:40 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CSL Limited is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Lyanne Harrison | BofA Global Research |